UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Diagnosis and management of primary central nervous system lymphoma

Cancer, 2017-11, Vol.123 (22), p.4314-4324

2017

Link zum Volltext

Verfügbarkeit prüfen

Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system

Cancer, 2022-01, Vol.128 (1), p.47-58

2022

Link zum Volltext

Verfügbarkeit prüfen

New Directions in Anti-Angiogenic Therapy for Glioblastoma

Neurotherapeutics, 2017-04, Vol.14 (2), p.321-332

2017

Link zum Volltext

Verfügbarkeit prüfen

Low‐Grade Gliomas

The oncologist (Dayton, Ohio), 2014-04, Vol.19 (4), p.403-413

2014

Link zum Volltext

Verfügbarkeit prüfen

Targeting Bruton's tyrosine kinase in primary central nervous system lymphoma

Current opinion in neurology, 2021-12, Vol.34 (6), p.848

2021

Link zum Volltext

Verfügbarkeit prüfen

Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma

Neuro-oncology (Charlottesville, Va.), 2019-02, Vol.21 (3), p.296-305

2019

Link zum Volltext

Verfügbarkeit prüfen

Introduction of novel agents in the treatment of primary CNS lymphoma

Neuro-oncology (Charlottesville, Va.), 2019-02, Vol.21 (3), p.306-313

2019

Link zum Volltext

Verfügbarkeit prüfen

Antiangiogenic therapy for glioblastoma: current status and future prospects

Clinical cancer research, 2014-11, Vol.20 (22), p.5612-5619

2014

Link zum Volltext

Verfügbarkeit prüfen

Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival

Proceedings of the National Academy of Sciences - PNAS, 2016-04, Vol.113 (16), p.4476-4481

2016

Link zum Volltext

Verfügbarkeit prüfen

Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages

Proceedings of the National Academy of Sciences - PNAS, 2016-04, Vol.113 (16), p.4470-4475

2016

Link zum Volltext

Verfügbarkeit prüfen

BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications

PloS one, 2011-03, Vol.6 (3), p.e17948-e17948

2011

Link zum Volltext

Verfügbarkeit prüfen

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

Journal of clinical oncology, 2013-09, Vol.31 (26), p.3212-3218

2013

Link zum Volltext

Verfügbarkeit prüfen

Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline

Journal of clinical oncology, 2017-01, Vol.35 (3), p.361-369

2017

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate

Nature communications, 2018-04, Vol.9 (1), p.1474-9, Article 1474

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma

Oncotarget, 2017-10, Vol.8 (45), p.79298-79304

2017

Link zum Volltext

Verfügbarkeit prüfen

Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate

The Journal of clinical investigation, 2013-09, Vol.123 (9), p.3659-3663

2013

Link zum Volltext

Verfügbarkeit prüfen

Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma

Clinical cancer research, 2016-09, Vol.22 (17), p.4452-4465

2016

Link zum Volltext

Verfügbarkeit prüfen

Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate

Clinical cancer research, 2016-04, Vol.22 (7), p.1632-1641

2016

Link zum Volltext

Verfügbarkeit prüfen

Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy

Nature medicine, 2013-09, Vol.19 (9), p.1178-1183

2013

Link zum Volltext

Verfügbarkeit prüfen

Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy

Acta neuropathologica, 2017-01, Vol.133 (1), p.1-3

2017

Link zum Volltext

Verfügbarkeit prüfen

Primary Vitreoretinal Lymphoma: A Report from an International Primary Central Nervous System Lymphoma Collaborative Group Symposium

The oncologist (Dayton, Ohio), 2011-11, Vol.16 (11), p.1589-1599

2011

Link zum Volltext

Verfügbarkeit prüfen

Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)

Neuro-oncology (Charlottesville, Va.), 2021-07, Vol.23 (7), p.1056-1071

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 520

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(483)
Mit Volltextzugriff
(481)

Publikationsform

Sprache

Englisch
(519)
Japanisch
(82)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Neuro-Oncology
(118)
Journal Of Clinical Oncology
(66)
Cancer Research
(23)
Clinical Cancer Research
(23)
Blood
(22)
Journal Of Neuro-Oncology
(17)
Cancer
(12)
The New England Journal Of Medicine
(12)
The Oncologist
(10)
Neuro-Oncology Advances
(9)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Diagnosis and management of primary central nervous system lymphoma

Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system

New Directions in Anti-Angiogenic Therapy for Glioblastoma

Low‐Grade Gliomas

A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment

Targeting Bruton's tyrosine kinase in primary central nervous system lymphoma

Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma

Introduction of novel agents in the treatment of primary CNS lymphoma

Antiangiogenic therapy for glioblastoma: current status and future prospects

Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival

Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages

BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion

Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma

Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate

Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma

Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate

Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy

Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy

Primary Vitreoretinal Lymphoma: A Report from an International Primary Central Nervous System Lymphoma Collaborative Group Symposium

Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)

A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma

Suchergebnisse filtern